One-year outcomes of intravitreal bevacizumab (avastin) therapy for XXXX .

@entity1 @entity455 @entity1127 @entity75 @entity3194 @entity12804 @entity3225
PURPOSE: To report on 1-year visual, anatomical, and angiographic responses with intravitreal bevacizumab for the treatment of @entity455 . METHODS: @entity1 with macula-involved, symptomatic @entity455 with initial best-corrected visual acuity of 20/400 or better and a minimal follow-up period of 12 months were retrospectively enrolled. Eyes were treated with intravitreal bevacizumab (2.5 mg) at baseline and monitored monthly for best-corrected visual acuity and central retinal thickness (by optical coherence tomography). Indocyanine green angiography was evaluated on a 6-month basis. Eyes were retreated on an "as-needed" basis according to visual and anatomical changes. RESULTS: A total of 35 eyes of 33 @entity1 were treated with a mean of 3.3 (range, 1-8) times of injection. Best-corrected visual acuity significantly improved from a mean logarithm of the minimum angle of resolution of 0.79    0.42 at baseline (Snellen equivalent, 20/123) to 0.69    0.47 (20/94), 0.66    0.45 (20/87), 0.67    0.44 (20/87), 0.67    0.48 (20/87), and 0.67    0.51 @entity12804 , and 12 months, respectively (P = 0.002, 0.0003, 0.0008, 0.017, and 0.02, respectively; paired Student's t-test). Central retinal thickness also significantly improved from a mean of 297    94  m at baseline to 215    58  m, 214    59  m, 218    79  m, 213    75  m, and 221    61  m at 1, 3, 6, 9, and 12 months, respectively (all P < 0.0001, paired Student's t-test). Indocyanine green angiography showed 3 of 32 eyes (9.4%) and 5 of 31 eyes (16.1%) with completely resolved @entity1127 and 11 of 32 eyes (34.4%) and 10 of 31 eyes (32.3%) with reduced @entity1127 at 6 and 12 months, respectively. No systemic complication or severe local complication, such as @entity3225 , was found. CONCLUSION: Intravitreal bevacizumab therapy has a favorable outcome in improving visual acuity and macular exudative changes in @entity1 with @entity455 . It can also moderately reduce @entity75 on @entity3194 angiography.
